This recall was prompted by a request from the US FDA to amend the risk assessment information related to the product, also noted on page one. The affected product is used for treating refractory complex partial seizures in patients aged two years and older, as detailed on page two. Cipla has not received any reports of adverse events related to this recall, which is being conducted with the knowledge of the U.S. Food and Drug Administration, mentioned on page three.
Cipla Limited has informed the Exchange regarding a revised press release dated December 15, 2023, titled "Revised Press Release - This is further to the press release submitted by the Company on 10th December 2023. It was brought to our attention by US FDA that there was information in our risk assessment that was not pertinent to this product. As a result we are reissuing a revised press release on the said matter.